Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.

Waddington CS, Walker WT, Oeser C, Reiner A, John T, Wilkins S, Casey M, Eccleston PE, Allen RJ, Okike I, Ladhani S, Sheasby E, Hoschler K, Andrews N, Waight P, Collinson AC, Heath PT, Finn A, Faust SN, Snape MD, Miller E, Pollard AJ.

BMJ. 2010 May 27;340:c2649. doi: 10.1136/bmj.c2649.

2.

Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants.

Ahmed SS, Schur PH, MacDonald NE, Steinman L.

J Autoimmun. 2014 May;50:1-11. doi: 10.1016/j.jaut.2014.01.033. Epub 2014 Feb 19. Review.

3.

Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.

Walker WT, Faust SN.

Expert Rev Vaccines. 2010 Dec;9(12):1385-98. doi: 10.1586/erv.10.141. Review.

PMID:
21105775
4.

Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta-analysis.

Yin JK, Khandaker G, Rashid H, Heron L, Ridda I, Booy R.

Influenza Other Respir Viruses. 2011 Sep;5(5):299-305. doi: 10.1111/j.1750-2659.2011.00229.x. Epub 2011 Mar 21. Review.

5.

Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults.

Tsai TF.

Infect Chemother. 2013 Jun;45(2):159-74. doi: 10.3947/ic.2013.45.2.159. Epub 2013 Jun 26. Review.

6.
7.

Effectiveness and safety of seasonal influenza vaccination in children with underlying respiratory diseases and allergy.

Kang JH.

Korean J Pediatr. 2014 Apr;57(4):164-70. doi: 10.3345/kjp.2014.57.4.164. Epub 2014 Apr 30. Review.

Supplemental Content

Support Center